EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Development and validation of a hierarchical approach for lymphoma classification using immunohistochemical markers

Jiming Xu, Yunfei Shi, Mengxuan Cui iD, Yao Wang, Wenhui Fan, Jingping Yun, Linfeng Li, Muyan Cai

Cancer Medicine · 2024-10 · 13 (20)

DOI: 10.1002/cam4.70120 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Cancer Medicine, online erschienen am 23.10.2024. Verfasst von Jiming Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Automation, Tsinghua University, Beijing, China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Immunohistochemistry, Lymphoma, Machine Learning. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Hebei Provincial Health and Family Planning Commission Scientific Research Fund Project, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Accurate lymphoma classification is critical for effective treatment and immunohistochemistry is a cost‐effective and time‐saving approach. Although several machine learning algorithms showed effective results, they focused on a specific task of classification but not the whole classification workflow, thus impractical to be applied in clinical settings. Thus, we aim to develop an effective and economic machine learning‐assisted system that can streamline the lymphoma differential diagnostic workflow using EBER in situ hybridization and immunohistochemical markers.

Methods

We included pathological reports diagnosed as lymphomas from two cancer centers (Sun Yat‐sen University Cancer Center and Peking University Cancer Hospital & Institute). We proposed a hierarchical approach that mimicked the human diagnostic process and employed simplified panels of markers to perform a series of interpretable classification. The diagnostic accuracy for lymphoma pathological subtypes and the markers saving ratio were investigated in both temporal independent population and external medical center.

Results

A total of 14,927 patients and corresponding immunohistochemical results from two cancer centers were included. The proposed system had high discriminative ability for differentiating lymphoma pathological subtypes (measured by mean AUC in three validation cohorts, non‐Hodgkin and Hodgkin lymphoma: 0.959; non‐Hodgkin subtypes: 0.983; B‐lymphoma subtypes: 0.868; T‐lymphoma subtypes: 0.962; DLBCL subtypes: 0.957). In addition, the system's well selected characteristics can contribute to the development of agreement on panels of markers for differential diagnosis and help minimize cost of immunohistochemical marker techniques (measured by marker saving ratio compared to real clinical settings, internal primary‐stage cohort: 16.45% saved, p < 0.001; internal later‐stage cohort: 21.73% saved, p < 0.001; external cohort: 3.67% saved, p < 0.001).

Conclusions

Machine learning‐based hierarchical system using EBER in situ hybridization and IHC markers was developed, which could streamline the workflow by sequentially determining each lymphoma pathological subtype. The proposed system proved to be effective and cost‐saving in independent and external validation, thus could be adopted affordably in future clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorImmunohistochemistryLymphomaMachine LearningHumansFemaleMaleMiddle AgedAdultAgedYoung AdultDiagnosis, DifferentialAdolescentLymphoma, Non-Hodgkin

Stichwörter der Autor:innen

diagnosisimmunohistochemistrylymphomasmachine learning

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Automation, Tsinghua University, Beijing, China.
  • Yidu Cloud Technology Inc, Beijing, China.
  • Key Laboratory of Carcinogenesis and Translational Research, Department of Pathology, Ministry of Education, Peking University Cancer Hospital and Institute, Beijing, China.
  • Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China.

ORCID-Profile: Mengxuan Cui

Förderung

  • National Key Research and Development Program of China
  • Hebei Provincial Health and Family Planning Commission Scientific Research Fund Project
  • National Natural Science Foundation of China

Zitieren

APA

Xu, J., Shi, Y., Cui, M., Wang, Y., Fan, W., Yun, J., Li, L., & Cai, M. (2024). Development and validation of a hierarchical approach for lymphoma classification using immunohistochemical markers. Cancer Medicine, 13(20). https://doi.org/10.1002/cam4.70120

Vancouver

Xu J, Shi Y, Cui M, Wang Y, Fan W, Yun J, et al. Development and validation of a hierarchical approach for lymphoma classification using immunohistochemical markers. Cancer Medicine. 2024;13(20). doi:10.1002/cam4.70120

BibTeX
@article{Xu2024,
  author = {Xu, Jiming and Shi, Yunfei and Cui, Mengxuan and Wang, Yao and Fan, Wenhui and Yun, Jingping and Li, Linfeng and Cai, Muyan},
  title = {Development and validation of a hierarchical approach for lymphoma classification using immunohistochemical markers},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {20},
  doi = {10.1002/cam4.70120}
}
Kostenlos starten →